Clinical trial / 2012
Resistant starch supplementation did not reduce colorectal cancer risk in Lynch syndrome carriers.
A randomized controlled trial evaluated 30 g daily resistant starch versus placebo for up to four years in 918 individuals with Lynch syndrome. Over a median follow-up of 52.7 months, 53 participants developed primary colorectal cancers. Intention-to-treat analysis showed no significant effect of resistant starch on time to first colorectal cancer (HR 1.40; 95% CI: 0.78-2.56; p = 0.26) or overall incidence rate (IRR 1.15; 95% CI: 0.66-2.00; p = 0.61).
- Study type
- Randomized controlled trial
- Who was studied
- 918 carriers of Lynch syndrome
- What was measured
- incidence of colorectal cancer
THE PAPER
Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
Mathers JC, Movahedi M, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans G, Maher ER, Bertario L, Bisgaard ML, Dunlop M, Ho JW, Hodgson S, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen H, Gerdes AM, Barker G, Crawford G, Elliott F, Pylvanainen K, Wijnen J, Fodde R, Lynch H, Bishop DT, Burn J, CAPP2 Investigators. Lancet Oncol, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.